Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 29Fallopian Tube Neoplasms 15Breast Neoplasms 10Carcinoma, Ovarian Epithelial 6Peritoneal Neoplasms 3Multiple Myeloma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Vaccinia 1Uterine Cervical Neoplasms 1Sarcoma, Kaposi 1Pelvic Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Low Grade Serous Ovarian Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Genital Neoplasms, Female 1Genetic Predisposition to Disease 1Endometrial Neoplasms 1Carcinoma 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

Gemcitabine 2liposomal doxorubicin 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Pafolacianine 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pelvic Neoplasms × liposomal doxorubicin × Clear all
NCT00191607 2007-01-26

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

Eli Lilly and Company

Phase 3 Completed
162 enrolled
Gynecologic

Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡